Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
A digital cognitive assessment was implemented in primary care to detect early dementia and guide next steps. The study found that 10.8% of eligible patients underwent the test, with 44.3% categorized as unimpaired and 13.7% as impaired.
Researchers identified CLU protein as a potential strategy to protect against Alzheimer's disease by increasing clusterin protein. Increased CLU protects the brain from amyloid plaques and loss of synapses, while identifying individuals most likely to respond based on their genetics.
A protein link between brain diseases and leaky blood vessels reveals that endothelial cell dysfunction plays a crucial role in the progression of neurodegenerative diseases. The study found that reduced TDP-43 levels lead to gaps in blood vessel walls, allowing toxic molecules to enter the brain.
Dr. Seymour Reichlin's remarkable career spanned five decades, marked by scientific excellence, mentorship, and generosity. His influence on neuroendocrinology has been profound, with ongoing contributions at age 100 revealing new insights into Alzheimer's disease and ecstatic mysticism.
A harmful form of tau protein directly damages blood vessels in the brain, leading to inflammation and weakening the brain's protective shield. The discovery highlights the importance of focusing on early neurovascular changes mediated by tau to prevent or slow down damage to the blood-brain barrier.
A study by the University of Eastern Finland reveals that traffic-derived ultrafine particles influence gene regulation in human olfactory mucosa cells, particularly affecting the PI3K/AKT signaling pathway. The findings suggest a potential link between air pollution and neurodegenerative diseases.
Researchers develop a simplified model of tau protein that forms disease-like fibrils, shedding light on the fundamental interactions underlying neurodegenerative diseases. The 'mini prion' can recreate the critical hallmarks of tauopathies, such as Alzheimer's disease.
A recent study used AI to discover that phosphoglycerate dehydrogenase (PHGDH) is a causal gene for spontaneous Alzheimer's disease. The researchers found that altering PHGDH expression levels can significantly impact the progression of the disease, suggesting a novel therapeutic target.
A new study from the University of Missouri suggests that exercise can improve brain health and mitigate cognitive decline, even when ketone production in the liver is impaired. The research found that endurance exercise can prevent cognitive impairment caused by compromised hepatic ketogenesis.
A multi-site clinical trial found that both low and moderate-high intensity exercise reduced cognitive decline in sedentary older adults with mild memory loss. The study showed that even low-intensity exercise may be beneficial for brain health, suggesting a promising new strategy to prevent or delay dementia.
A recent study published in The Gerontologist found no difference in spatial working memory between older people with autistic traits and those who are neurotypical. Most participants maintained their cognitive ability over time, suggesting that autism is not associated with increased risk of age-related cognitive decline.
The Swiss Memory Clinics network has released new national guidelines on the use of anti-amyloid monoclonal antibodies, such as Lecanemab and Donanemab, for treating Alzheimer's disease. The guidelines outline criteria for patient selection, biomarker confirmation, and infrastructure requirements to support safe treatment delivery.
A new study led by University College London researchers found that people with Alzheimer's disease scored slightly higher on a measure of empathy than peers with mild cognitive impairment. Despite this, emotional reactivity to negative emotions was heightened among those with Alzheimer's disease, contributing to difficulties regulatin...
The US Cost of Dementia Project estimates total economic burden at $781 billion, accounting for lost earnings, diminished quality of life, and unpaid care. The project aims to inform evidence-based policies reducing dementia's financial impact.
A team of researchers from Goethe University and Kiel University has discovered a way to prevent the formation of harmful protein aggregates in cultured cells. The study found that linking TDP-43 with SUMO prevents its aggregation, suggesting a potential new approach for treating ALS and other neurodegenerative diseases.
Researchers found that ATP regulates protein condensation and cytoplasm viscosity, preventing harmful protein aggregates. Boosting ATP production decreases viscosity, dispersing existing and preventing future protein aggregations.
The Davos Alzheimer's Collaborative has partnered with PacBio to advance Alzheimer's disease research in North Africa. The collaboration aims to develop a comprehensive multi-omics dataset to better understand the genetics of Alzheimer's disease and dementia in diverse global populations.
Researchers at UNM hope to launch human clinical trials for a vaccine targeting the tau protein associated with Alzheimer's dementia. The experimental vaccine generated a robust immune response in both mice and non-human primates, building on earlier research.
A Northwestern University study found virtual group singing can be an effective tool for promoting well-being and social connection during isolation. Participants reported high satisfaction with the sing-alongs, which helped evoke emotional resonance and promote intellectual engagement.
A new study from Columbia University Mailman School of Public Health found significant associations between cognition and established risk factors for Alzheimer's disease in individuals aged 24-44. The researchers used biomarkers related to cognitive impairment and cardiovascular health to predict long-term trajectories of cognitive de...
Researchers at UC Irvine develop a cell-based platform to deliver disease-fighting proteins throughout the brain, reducing inflammation, preserving neurons, and reversing neurodegeneration in mice. The engineered microglia can detect disease-specific changes and release enzymes to break down toxic proteins.
A study by Baylor College of Medicine researchers identifies 123 genes associated with increased AD risk in humans, including MTCH2, which shows promise as a potential therapeutic target. The team also found that reversing the alterations in these genes has a neuroprotective effect in living organisms.
Calmming the brain's immune cells via norepinephrine may prevent or lessen Alzheimer's inflammation and damage. The study highlights a key role of norepinephrine in mitigating early inflammatory changes and neuronal injury.
Researchers at Tokyo University of Science have made breakthroughs in delivering gene-targeting compounds to the brain, using cholesterol-modified oligonucleotides that can penetrate the cerebral cortex beyond the blood vessels. This could lead to new treatments for diseases such as Alzheimer's and Parkinson's, as well as brain cancers.
A new study has found that older age is linked to higher levels of three dementia biomarkers in the blood. Researchers also discovered sex differences in biomarker levels, with female participants having higher levels of glial acidic proteins.
A study has identified an early blood marker for hereditary Alzheimer's disease, beta-synuclein, which can detect neurodegeneration up to 11 years before dementia symptoms. This biomarker could help with early diagnosis and treatment, improving the potential of new medicines for Alzheimer's.
A novel cannula delivery system allows repeated, nondisruptive delivery of imaging agents to the mouse brain during long-term multiphoton microscopy. This innovation enhances longitudinal studies on brain function, disease progression, and potential treatments.
A study published in JAMA Neurology found that GLP-1RAs and SGLT2is may have neuroprotective effects for people with Type 2 diabetes and those without diabetes. These findings suggest that these medications may slow the rate of cognitive decline in Alzheimer’s patients.
Dr. Rhonda Winegar investigates the effectiveness of music therapy in supporting neurological care, including its ability to reduce anxiety and depression in Alzheimer's patients. Her research also highlights its potential to regulate heart rate and blood pressure, as well as improve motor function in individuals with Parkinson's disease.
Women who enter menopause before age 40 experience worse cognitive decline compared to those entering menopause after 50. This association may help clinicians assess patient risk of developing dementia. Further research is needed to understand the underlying mechanisms and design potential treatments.
A novel AI tool, RibbonFold, predicts the structures of amyloids, revealing previously overlooked nuances in their formation and evolution. This breakthrough may reshape how researchers approach neurodegenerative disease treatment and offers a scalable method for analyzing harmful protein aggregates.
Researchers found that SIRT2, a previously unknown enzyme, plays a key role in excessive GABA production associated with Alzheimer's disease. This process leads to brain inflammation and memory impairment. By targeting SIRT2, scientists can selectively block its harmful effects on memory without affecting other brain functions.
Researchers at Ohio State University Wexner Medical Center have discovered a new way that neurons act in neurodegeneration by studying human neural organoids from patients with frontotemporal lobar degeneration (FTLD). They found GRAMD1B plays a significant role in managing cholesterol and lipid stores, which are linked to brain diseas...
A comprehensive longitudinal analysis of obesity trajectories identified distinct patterns affecting brain morphology, function, and cognition in middle-aged and older adults. The study suggests sustained obesity accelerates brain aging, highlighting the clinical importance of long-term monitoring and management.
Researchers have validated a blood test for early detection of Alzheimer's disease, achieving over 90% accuracy in hospital patients. The test uses a biomarker called phospho-tau217 and has the potential to reduce costs associated with current diagnostic tests, improving access to care and treatment.
Researchers have identified Tim-3 as a promising therapeutic target for Alzheimer's disease by targeting microglia in the brain. Deleting Tim-3 helps kickstart plaque removal, reduce neuroinflammation, and limit cognitive impairment.
Researchers have initiated a clinical trial using an investigational medicine to lower amyloid precursor protein, targeting Alzheimer's disease in adults with Down syndrome. The study aims to prevent the development of Alzheimer's disease by addressing its underlying genetic cause.
A new analytical method has been developed to measure plasma P-tau217, a blood-based marker that can change several years before Alzheimer's symptoms appear. The fully automated method demonstrated high accuracy of over 90% in various settings, including primary care and specialized memory clinics.
A study published by the American Academy of Neurology found that heavy drinkers have an increased risk of brain lesions and signs of brain injury, including hyaline arteriolosclerosis and tau tangles. Heavy drinking was also associated with lower brain mass ratio and worse cognitive abilities.
A new study published by the American Academy of Neurology found that having a father with Alzheimer's disease may be associated with a greater spread of tau protein in the brain. Female participants also showed a heavier buildup of tau protein, highlighting potential vulnerabilities.
Scientists have discovered a novel regulator of the mitochondrial sodium-calcium exchanger (NCLX), which helps maintain calcium balance in mitochondria. The discovery of TMEM65 could lead to new therapeutic agents to combat calcium overload associated with heart failure and Alzheimer's disease.
A new Northwestern University study finds that NU-9 improves neuron health in animal models of Alzheimer's disease by addressing the underlying mechanisms of misfolded proteins. The drug reduces protein buildup and prevents inflammation, showing potential for treating neurodegenerative diseases.
A novel computational tool called CHOIR can accurately distinguish cells of different identities in complex biological samples, helping scientists pinpoint the discordant cells that disrupt harmony and promote disease. CHOIR overcomes limitations of existing tools by avoiding personal bias and introducing unbiased statistical frameworks.
Research reveals that GLP-1RAs and SGLT2i medications significantly reduce the risk of Alzheimer's disease and related dementias in people with type 2 diabetes. No significant difference was found between these two treatments.
Researchers at Temple University have discovered a new way to block the enzyme DLK, which plays a key role in neurodegenerative diseases. The breakthrough approach protects damaged neurons while preserving healthy neuron function.
Mass General Brigham researchers have identified 17 modifiable risk factors shared by stroke, dementia, and late-life depression. Modifying any one of these risk factors can reduce the risk of all three conditions, providing an opportunity to simultaneously reduce the burden of age-related brain diseases.
A new study published in Nature Medicine has investigated the potential of specific biomarkers to predict dementia risk up to ten years before diagnosis. The study found that low levels of certain biomarkers may rule out future dementia, but elevated levels alone are not reliable for identification.
A new compound has been discovered that shows neuroprotective and anti-inflammatory effects in two murine models of Alzheimer’s disease. The compound inhibits soluble epoxide hydrose (sEH), increasing levels of epoxyeicosatrienoic acids, which promote neuroprotection and reduce neuroinflammation.
A new study by UCL researchers found that people with visual Alzheimer's disease have a unique distribution of proteins and markers in their brain, leading to symptoms such as reading difficulties. In contrast, those with memory-led Alzheimer's disease have different protein patterns, resulting in symptoms like memory loss.
Researchers discovered senolytics can target Alzheimer's disease-associated brain enzymes AChE and BChE without affecting healthy ones. This selective approach may lead to safer treatments that improve memory and reduce inflammation in older adults.
Cognitive neuroscientists are using VR to develop innovative ways to assess cognitive decline, particularly in identifying age-related differences in spatial memory navigation. The study found significant impacts on memory performance due to the build-up of Alzheimer's proteins in the brain.
A study published in GeroScience found that weight training improves memory and brain anatomy in older adults with mild cognitive impairment. The results showed that strength training protected against atrophy in key brain areas associated with Alzheimer's disease.
Researchers at UCalgary have discovered a protein called CD2AP that may hold the key to reducing Alzheimer's disease risk. Levels of this protein are lower in patients with AD, and its absence affects memory function, particularly in males. The study suggests a sex-dependent link between vascular system health and brain function.
Researchers developed a blood test that accurately diagnoses Alzheimer's disease and measures its progression. The test correlates with the amount of tau aggregates in the brain, distinguishing between early- and late-stage diseases.
A recent study found that individuals with reduced slow wave sleep and rapid eye movement sleep had smaller volumes in critical brain regions, particularly the inferior parietal region. This association suggests a potential link between sleep deficiency and brain atrophy, which may increase the risk of Alzheimer's disease.
Researchers at Mayo Clinic are conducting a study to understand the factors that contribute to rapid progression of dementia in patients with Alzheimer's disease and Related Dementias. The team aims to identify biomarkers and disease-modifying targets that can improve diagnosis and treatment outcomes for these patients.
A new study from USC Dornsife's Brain and Creativity Institute found that nostalgic music engages the brain's default mode network linked to memory and self-reflection, as well as its reward circuitry. This discovery could support emotional well-being and cognitive function in individuals with memory impairments.
Researchers found that neurons use natural forces to keep their connections strong, and disruptions in these processes may be an early sign of Alzheimer's disease. The study provides new insights into neuronal connections and offers a potential target for therapies aimed at keeping the brain healthy as we age.
Researchers found that brain regions with higher cholesterol demands, like the Locus Coeruleus, are more vulnerable to Alzheimer's disease. The study suggests potential therapeutic targets for early treatment of the disease.
Scientists have long believed that cells respond to stress in a linear chain of events, but a new study reveals a more complex 'split-integrated stress response' that can be fine-tuned depending on the type and intensity of stress. This flexibility could lead to new targets for treating cancer and neurodegenerative diseases.